Logo image of VYGR

VOYAGER THERAPEUTICS INC (VYGR) Stock Fundamental Analysis

NASDAQ:VYGR - Nasdaq - US92915B1061 - Common Stock - Currency: USD

5.45  -0.16 (-2.85%)

After market: 5.52 +0.07 (+1.28%)

Fundamental Rating

5

VYGR gets a fundamental rating of 5 out of 10. The analysis compared the fundamentals against 572 industry peers in the Biotechnology industry. While VYGR has a great health rating, its profitability is only average at the moment. VYGR is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

6

1. Profitability

1.1 Basic Checks

In the past year VYGR was profitable.
VYGR had a negative operating cash flow in the past year.
The reported net income has been mixed in the past 5 years: VYGR reported negative net income in multiple years.
The reported operating cash flow has been mixed in the past 5 years: VYGR reported negative operating cash flow in multiple years.
VYGR Yearly Net Income VS EBIT VS OCF VS FCFVYGR Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 50M -50M 100M -100M

1.2 Ratios

VYGR's Return On Assets of 6.07% is amongst the best of the industry. VYGR outperforms 95.58% of its industry peers.
Looking at the Return On Equity, with a value of 7.84%, VYGR belongs to the top of the industry, outperforming 95.04% of the companies in the same industry.
VYGR has a Return On Invested Capital of 2.46%. This is amongst the best in the industry. VYGR outperforms 94.16% of its industry peers.
Industry RankSector Rank
ROA 6.07%
ROE 7.84%
ROIC 2.46%
ROA(3y)-9.39%
ROA(5y)-5.28%
ROE(3y)-32.51%
ROE(5y)-23.51%
ROIC(3y)N/A
ROIC(5y)N/A
VYGR Yearly ROA, ROE, ROICVYGR Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 50 -50 -100 -150

1.3 Margins

With an excellent Profit Margin value of 15.80%, VYGR belongs to the best of the industry, outperforming 96.11% of the companies in the same industry.
In the last couple of years the Profit Margin of VYGR has grown nicely.
The Operating Margin of VYGR (7.25%) is better than 94.87% of its industry peers.
VYGR's Operating Margin has improved in the last couple of years.
Industry RankSector Rank
OM 7.25%
PM (TTM) 15.8%
GM N/A
OM growth 3Y44.98%
OM growth 5YN/A
PM growth 3Y35.13%
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
VYGR Yearly Profit, Operating, Gross MarginsVYGR Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 -200 -400 -600 -800 -1K

More info and screens

7

2. Health

2.1 Basic Checks

The Return on Invested Capital (ROIC) is below the Cost of Capital (WACC), so VYGR is destroying value.
The number of shares outstanding for VYGR has been increased compared to 1 year ago.
VYGR has more shares outstanding than it did 5 years ago.
VYGR has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
VYGR Yearly Shares OutstandingVYGR Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 10M 20M 30M 40M
VYGR Yearly Total Debt VS Total AssetsVYGR Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 100M 200M 300M

2.2 Solvency

VYGR has an Altman-Z score of 2.37. This is not the best score and indicates that VYGR is in the grey zone with still only limited risk for bankruptcy at the moment.
The Altman-Z score of VYGR (2.37) is better than 72.92% of its industry peers.
There is no outstanding debt for VYGR. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 2.37
ROIC/WACC0.23
WACC10.75%
VYGR Yearly LT Debt VS Equity VS FCFVYGR Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 100M -100M 200M

2.3 Liquidity

A Current Ratio of 8.45 indicates that VYGR has no problem at all paying its short term obligations.
VYGR's Current ratio of 8.45 is fine compared to the rest of the industry. VYGR outperforms 73.98% of its industry peers.
A Quick Ratio of 8.45 indicates that VYGR has no problem at all paying its short term obligations.
Looking at the Quick ratio, with a value of 8.45, VYGR is in the better half of the industry, outperforming 74.16% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 8.45
Quick Ratio 8.45
VYGR Yearly Current Assets VS Current LiabilitesVYGR Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 100M 200M 300M

More info and screens

4

3. Growth

3.1 Past

The earnings per share for VYGR have decreased strongly by -42.28% in the last year.
The Earnings Per Share has been growing by 48.16% on average over the past years. This is a very strong growth
Looking at the last year, VYGR shows a small growth in Revenue. The Revenue has grown by 3.33% in the last year.
The Revenue has been growing by 101.11% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)-42.28%
EPS 3Y48.16%
EPS 5YN/A
EPS Q2Q%72.88%
Revenue 1Y (TTM)3.33%
Revenue growth 3Y13.48%
Revenue growth 5Y101.11%
Sales Q2Q%433.79%

3.2 Future

Based on estimates for the next years, VYGR will show a very negative growth in Earnings Per Share. The EPS will decrease by -16.29% on average per year.
Based on estimates for the next years, VYGR will show a decrease in Revenue. The Revenue will decrease by -7.89% on average per year.
EPS Next Y-130.32%
EPS Next 2Y-58.38%
EPS Next 3Y-33.98%
EPS Next 5Y-16.29%
Revenue Next Year-45.77%
Revenue Next 2Y-35.98%
Revenue Next 3Y-20.31%
Revenue Next 5Y-7.89%

3.3 Evolution

The EPS growth rate is decreasing: in the next years the growth will be less than in the last years.
The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
VYGR Yearly Revenue VS EstimatesVYGR Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 100M 200M 300M 400M
VYGR Yearly EPS VS EstimatesVYGR Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 0 -5 -10

More info and screens

3

4. Valuation

4.1 Price/Earnings Ratio

With a Price/Earnings ratio of 7.68, the valuation of VYGR can be described as very cheap.
Based on the Price/Earnings ratio, VYGR is valued cheaply inside the industry as 98.23% of the companies are valued more expensively.
VYGR's Price/Earnings ratio indicates a rather cheap valuation when compared to the S&P500 average which is at 28.46.
VYGR is expected to report negative earnings next year, which makes the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE 7.68
Fwd PE N/A
VYGR Price Earnings VS Forward Price EarningsVYGR Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA -16.04
VYGR Per share dataVYGR EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 4 6

4.3 Compensation for Growth

VYGR has a very decent profitability rating, which may justify a higher PE ratio.
A cheap valuation may be justified as VYGR's earnings are expected to decrease with -33.98% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-58.38%
EPS Next 3Y-33.98%

More info and screens

0

5. Dividend

5.1 Amount

VYGR does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

VOYAGER THERAPEUTICS INC

NASDAQ:VYGR (1/31/2025, 8:00:30 PM)

After market: 5.52 +0.07 (+1.28%)

5.45

-0.16 (-2.85%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-12 2024-11-12/amc
Earnings (Next)N/A N/A
Inst Owners69.44%
Inst Owner Change-0.04%
Ins Owners0.88%
Ins Owner Change0.52%
Market Cap297.73M
Analysts88.24
Price Target17.44 (220%)
Short Float %5.43%
Short Ratio4.95
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)61.17%
Min EPS beat(2)56.91%
Max EPS beat(2)65.43%
EPS beat(4)4
Avg EPS beat(4)175.61%
Min EPS beat(4)55.44%
Max EPS beat(4)524.68%
EPS beat(8)7
Avg EPS beat(8)122.4%
EPS beat(12)9
Avg EPS beat(12)104.24%
EPS beat(16)12
Avg EPS beat(16)80.58%
Revenue beat(2)2
Avg Revenue beat(2)154.78%
Min Revenue beat(2)103.06%
Max Revenue beat(2)206.51%
Revenue beat(4)4
Avg Revenue beat(4)185.17%
Min Revenue beat(4)103.06%
Max Revenue beat(4)327.88%
Revenue beat(8)7
Avg Revenue beat(8)139.79%
Revenue beat(12)9
Avg Revenue beat(12)112.15%
Revenue beat(16)10
Avg Revenue beat(16)75.54%
PT rev (1m)-3.21%
PT rev (3m)-1.35%
EPS NQ rev (1m)0%
EPS NQ rev (3m)14.5%
EPS NY rev (1m)0%
EPS NY rev (3m)34.42%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)54.33%
Revenue NY rev (1m)-0.66%
Revenue NY rev (3m)30.55%
Valuation
Industry RankSector Rank
PE 7.68
Fwd PE N/A
P/S 1.82
P/FCF N/A
P/OCF N/A
P/B 0.9
P/tB 0.9
EV/EBITDA -16.04
EPS(TTM)0.71
EY13.03%
EPS(NY)-1.57
Fwd EYN/A
FCF(TTM)-0.53
FCFYN/A
OCF(TTM)-0.45
OCFYN/A
SpS3
BVpS6.05
TBVpS6.05
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA 6.07%
ROE 7.84%
ROCE 3.11%
ROIC 2.46%
ROICexc 25.72%
ROICexgc 25.72%
OM 7.25%
PM (TTM) 15.8%
GM N/A
FCFM N/A
ROA(3y)-9.39%
ROA(5y)-5.28%
ROE(3y)-32.51%
ROE(5y)-23.51%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3Y62.34%
ROICexcg growth 5YN/A
ROICexc growth 3Y62.34%
ROICexc growth 5YN/A
OM growth 3Y44.98%
OM growth 5YN/A
PM growth 3Y35.13%
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0.38
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA 0
Cap/Depr 81.45%
Cap/Sales 2.52%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 8.45
Quick Ratio 8.45
Altman-Z 2.37
F-Score3
WACC10.75%
ROIC/WACC0.23
Cap/Depr(3y)48.23%
Cap/Depr(5y)148.03%
Cap/Sales(3y)3.9%
Cap/Sales(5y)5.23%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-42.28%
EPS 3Y48.16%
EPS 5YN/A
EPS Q2Q%72.88%
EPS Next Y-130.32%
EPS Next 2Y-58.38%
EPS Next 3Y-33.98%
EPS Next 5Y-16.29%
Revenue 1Y (TTM)3.33%
Revenue growth 3Y13.48%
Revenue growth 5Y101.11%
Sales Q2Q%433.79%
Revenue Next Year-45.77%
Revenue Next 2Y-35.98%
Revenue Next 3Y-20.31%
Revenue Next 5Y-7.89%
EBIT growth 1Y-72.64%
EBIT growth 3Y64.52%
EBIT growth 5YN/A
EBIT Next Year-254.45%
EBIT Next 3Y-65.68%
EBIT Next 5Y-41.02%
FCF growth 1Y-418.71%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-325.34%
OCF growth 3YN/A
OCF growth 5YN/A